BackVertex Pharmaceuticals Overview

Vertex Pharmaceuticals Current Cash

Track Vertex Pharmaceuticals's current cash ($5.5B) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$5.49B

Peer average

Loading

Vertex Pharmaceuticals Current Cash History

Loading

Vertex Pharmaceuticals vs. peers: Current Cash Comparison

Loading

Vertex Pharmaceuticals Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Vertex Pharmaceuticals (VRTX) FAQ

As of the most recent data (March 2026), VRTX shows a current cash of $5.5B. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, VRTX's current cash is now $5.5B (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Vertex Pharmaceuticals is outperforming or lagging.

Tracking VRTX's current cash over time shows whether Vertex Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $5.5B In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has Vertex Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $5.5B) with ownership activity and broader fundamentals.

Vertex Pharmaceuticals's current cash is $5.5B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.